BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Speciale A, Muscarà C, Molonia MS, Cristani M, Cimino F, Saija A. Recent Advances in Glycyrrhetinic Acid-Functionalized Biomaterials for Liver Cancer-Targeting Therapy. Molecules 2022;27:1775. [PMID: 35335138 DOI: 10.3390/molecules27061775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhai B, Sun J, Shi Y, Zhang X, Zou J, Cheng J, Fan Y, Guo D, Tian H. Review targeted drug delivery systems for norcantharidin in cancer therapy. J Nanobiotechnol 2022;20:509. [DOI: 10.1186/s12951-022-01703-3] [Reference Citation Analysis]
2 Langer D, Mlynarczyk DT, Dlugaszewska J, Tykarska E. Potential of glycyrrhizic and glycyrrhetinic acids against influenza type A and B viruses: A perspective to develop new anti-influenza compounds and drug delivery systems. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114934] [Reference Citation Analysis]
3 Zhang G, Yun Y, Lin C, Li H. Predictive Value of MRI with Serum Lectin-Reactive Alpha-Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation. Evid Based Complement Alternat Med 2022;2022:5132135. [PMID: 35911145 DOI: 10.1155/2022/5132135] [Reference Citation Analysis]